KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics


KalVista Pharmaceuticals, Inc. (KALV)

Today's Latest Price: $15.24 USD

0.53 (-3.36%)

Updated Oct 23 6:55pm

Add KALV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KALV Stock Summary

  • For KALV, its debt to operating expenses ratio is greater than that reported by merely 5.42% of US equities we're observing.
  • With a price/sales ratio of 30.72, KalVista Pharmaceuticals Inc has a higher such ratio than 94.25% of stocks in our set.
  • Revenue growth over the past 12 months for KalVista Pharmaceuticals Inc comes in at -40.92%, a number that bests just 5.74% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to KalVista Pharmaceuticals Inc, a group of peers worth examining would be NTLA, NXTC, VBLT, XENE, and SYBX.
  • Visit KALV's SEC page to see the company's official filings. To visit the company's web site, go to www.kalvista.com.

KALV Stock Price Chart Interactive Chart >

Price chart for KALV

KALV Price/Volume Stats

Current price $15.24 52-week high $19.41
Prev. close $15.77 52-week low $5.61
Day low $14.85 Volume 76,200
Day high $15.80 Avg. volume 116,398
50-day MA $13.66 Dividend yield N/A
200-day MA $12.27 Market Cap 272.92M

KalVista Pharmaceuticals, Inc. (KALV) Company Bio


KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.


KALV Latest News Stream


Event/Time News Detail
Loading, please wait...

KALV Latest Social Stream


Loading social stream, please wait...

View Full KALV Social Stream

Latest KALV News From Around the Web

Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.

KalVista Pharmaceticals EPS misses by $0.01

KalVista Pharmaceticals (KALV): FQ1 GAAP EPS of -$0.61 misses by $0.01.Cash, cash equivalents and marketable securities were $64.3M.Press Release...

Seeking Alpha | September 14, 2020

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase 2 trial has met its enrollment target and data is expected before the end of this year. We believe K

Business Wire | September 14, 2020

KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio ar

Business Wire | September 11, 2020

KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be avail

Business Wire | August 3, 2020

Need To Know: Analysts Are Much More Bullish On KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Revenues

Celebrations may be in order for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shareholders, with the analysts...

Yahoo | July 2, 2020

Read More 'KALV' Stories Here

KALV Price Returns

1-mo 18.23%
3-mo 37.79%
6-mo 28.93%
1-year 33.33%
3-year 20.95%
5-year -68.17%
YTD -14.43%
2019 -9.82%
2018 102.56%
2017 37.91%
2016 -86.05%
2015 N/A

Continue Researching KALV

Want to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:

KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7236 seconds.